Clinical Trial Update: Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating genotype-guided targeted agents plus an EZH2 inhibitor in primary refractory peripheral T-cell lymphoma, not yet recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Snippet

Sponsor: Ruijin Hospital | Conditions: PTCL, Refractory | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING